{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:29:01Z","timestamp":1759048141283},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"S5","license":[{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2004,9]]},"DOI":"10.1007\/s00415-004-1509-6","type":"journal-article","created":{"date-parts":[[2004,11,5]],"date-time":"2004-11-05T11:41:57Z","timestamp":1099654917000},"page":"v57-v64","source":"Crossref","is-referenced-by-count":9,"title":["Alternatives to current disease-modifying treatment in MS: what do we need and what can we expect in the future?"],"prefix":"10.1007","volume":"251","author":[{"given":"Ludwig","family":"Kappos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Kuhle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Achim","family":"Gass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lutz","family":"Achtnichts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernst-Wilhelm","family":"Radue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(98)03334-0","volume":"352","author":"PRISMS","year":"1998","unstructured":"PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing\/remitting multiple sclerosis. Lancet 352:1498?1504","journal-title":"Lancet"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/1531-8249(199908)46:2<197::AID-ANA9>3.0.CO;2-P","volume":"46","author":"Li","year":"1999","unstructured":"Li DK, Paty DW, the UBC MS\/MRI Analysis Research Group and the PRISMS Study Group (1999) Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Ann Neurol 46:197?206","journal-title":"Ann Neurol"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1212\/WNL.56.12.1628","volume":"56","author":"PRISMS","year":"2001","unstructured":"PRISMS Study Group and the University of British Columbia MS\/MRI Analysis Group (2001) PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 56:1628?1636","journal-title":"Neurology"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1212\/WNL.43.4.655","volume":"43","author":"The","year":"1993","unstructured":"The IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655?661","journal-title":"Neurology"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1212\/WNL.45.7.1277","volume":"45","author":"The","year":"1995","unstructured":"The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS\/MRI Analysis Group (1995) Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45:1277?1285","journal-title":"Neurology"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ana.410390304","volume":"39","author":"Jacobs","year":"1996","unstructured":"Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE 3rd, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH, et al. and the Multiple Sclerosis Collaborative Research Group (MSCRG) (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39:285?294","journal-title":"Ann Neurol"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1212\/WNL.45.7.1268","volume":"45","author":"Johnson","year":"1995","unstructured":"Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB and the Copolymer 1 Multiple Sclerosis Study Group (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology 45:1268?1276","journal-title":"Neurology"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1212\/WNL.43.4.662","volume":"43","author":"Paty","year":"1993","unstructured":"Paty DW, Li DK, UBC MS\/MRI Study Group and the IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:662?667","journal-title":"Neurology"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1212\/01.WNL.0000034080.43681.DA","volume":"59","author":"Panitch","year":"2002","unstructured":"Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, O?Connor P, Monaghan E, Li D, Weinshenker B and the EVIDENCE Study Group (2002) Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial. Neurology 59:1496?1506","journal-title":"Neurology"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0165-5728(99)00029-6","volume":"99","author":"Rothuizen","year":"1999","unstructured":"Rothuizen LE, Buclin T, Spertini F, Trinchard I, Munafo A, Buchwalder PA, Ythier A, Biollaz J (1999) Influence of interferon beta-1a dose frequency on PBMC cytokine secretion and biological effect markers. J Neuroimmunol 99:131?141","journal-title":"J Neuroimmunol"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1212\/01.WNL.0000095425.84407.39","volume":"61","author":"Goodin","year":"2003","unstructured":"Goodin DS, Arnason BG, Coyle PK, Frohman EM, Paty DW and the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology (2003) The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 61:1332?1338","journal-title":"Neurology"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(02)12023-X","volume":"360","author":"Hartung","year":"2002","unstructured":"Hartung HP, Gonsette R, Konig N, Kwiecinski H, Guseo A, Morrissey SP, Krapf H, Zwingers T and the Mitoxantrone in Multiple Sclerosis Study Group (MIMS) (2002) Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 360:2018?2025","journal-title":"Lancet"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1365-2249.2004.02344.x","volume":"135","author":"Weilbach","year":"2004","unstructured":"Weilbach FX, Chan A, Toyka KV, Gold R (2004) The cardioprotector dexrazoxane augments therapeutic efficacy of mitoxantrone in experimental autoimmune encephalomyelitis. Clin Exp Immunol 135:49?55","journal-title":"Clin Exp Immunol"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0268-960X(03)00022-5","volume":"17","author":"Fassas","year":"2003","unstructured":"Fassas A, Kimiskidis VK (2003) Stem cell transplantation for multiple sclerosis: what is the evidence? Blood Rev 17:233?240","journal-title":"Blood Rev"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1007\/s00415-002-0800-7","volume":"249","author":"Fassas","year":"2002","unstructured":"Fassas A, Passweg JR, Anagnostopoulos A, Kazis A, Kozak T, Havrdova E, Carreras E, Graus F, Kashyap A, Openshaw H, Schipperus M, Deconinck E, Mancardi G, Marmont A, Hansz J, Rabusin M, Zuazu Nagore FJ, Besalduch J, Dentamaro T, Fouillard L, Hertenstein B, La Nasa G, Musso M, Papineschi F, Rowe JM, Saccardi R, Steck A, Kappos L, Gratwohl A, Tyndall A, Samijn J, Samign J and the Autoimmune Disease Working Party of the EBMT (European Group for Blood and Marrow Transplantation) (2002) Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study. J Neurol 249:1088?1097","journal-title":"J Neurol"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1191\/1352458502ms838oa","volume":"8","author":"Hoogervorst","year":"2002","unstructured":"Hoogervorst EL, Polman CH, Barkhof F (2002) Cerebral volume changes in multiple sclerosis patients treated with high-dose intravenous methylprednisolone. Mult Scler 8:415?419","journal-title":"Mult Scler"},{"key":"CR17","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1212\/WNL.59.5.688","volume":"59","author":"Rao","year":"2002","unstructured":"Rao AB, Richert N, Howard T, Lewis BK, Bash CN, McFarland HF, Frank JA (2002) Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFNbeta-1b. Neurology 59:688?694","journal-title":"Neurology"},{"key":"CR18","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1212\/WNL.58.2.314","volume":"58","author":"Calabresi","year":"2002","unstructured":"Calabresi PA, Wilterdink JL, Rogg JM, Mills P, Webb A, Whartenby KA (2002) An open-label trial of combination therapy with interferon beta-1a and oral methotrexate in MS. Neurology 58:314?317","journal-title":"Neurology"},{"key":"CR19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000074912","volume":"51","author":"Lus","year":"2004","unstructured":"Lus G, Romano F, Scuotto A, Accardo C, Cotrufo R (2004) Azathioprine and interferon beta(1a) in relapsing-remitting multiple sclerosis patients: increasing efficacy of combined treatment. Eur Neurol 51:15?20","journal-title":"Eur Neurol"},{"key":"CR20","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/jnnp.71.3.404","volume":"71","author":"Patti","year":"2001","unstructured":"Patti F, Cataldi ML, Nicoletti F, Reggio E, Nicoletti A, Reggio A (2001) Combination of cyclophosphamide and interferon-beta halts progression in patients with rapidly transitional multiple sclerosis. J Neurol Neurosurg Psychiatry 71:404?407","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"CR21","doi-asserted-by":"crossref","first-page":"6418","DOI":"10.4049\/jimmunol.172.10.6418","volume":"172","author":"Mastronardi","year":"2004","unstructured":"Mastronardi FG, Min W, Wang H, Winer S, Dosch M, Boggs JM, Moscarello MA (2004) Attenuation of experimental autoimmune encephalomyelitis and nonimmune demyelination by IFN-beta plus vitamin B12: treatment to modify notch-1\/sonic hedgehog balance. J Immunol 172:6418?6426","journal-title":"J Immunol"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1093\/jnci\/94.13.1010","volume":"94","author":"Bauer","year":"2002","unstructured":"Bauer JA, Morrison BH, Grane RW, Jacobs BS, Dabney S, Gamero AM, Carnevale KA, Smith DJ, Drazba J, Seetharam B, Lindner DJ (2002) Effects of interferon beta on transcobalamin II-receptor expression and antitumor activity of nitrosylcobalamin. J Natl Cancer Inst 94:1010?1019","journal-title":"J Natl Cancer Inst"},{"key":"CR23","first-page":"173","volume":"37","author":"Yamashiki","year":"1992","unstructured":"Yamashiki M, Nishimura A, Kosaka Y (1992) Effects of methylcobalamin (vitamin B12) on in vitro cytokine production of peripheral blood mononuclear cells. J Clin Lab Immunol 37:173?182","journal-title":"J Clin Lab Immunol"},{"key":"CR24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJMoa020696","volume":"348","author":"Miller","year":"2003","unstructured":"Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA, Willmer-Hulme AJ, Dalton CM, Miszkiel KA, O?Connor PW and the International Natalizumab Multiple Sclerosis Trial Group (2003) A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348:15?23","journal-title":"N Engl J Med"},{"key":"CR25","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa020732","volume":"348","author":"Ghosh","year":"2003","unstructured":"Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, Vyhnalek P, Zadorova Z, Palmer T, Donoghue S and the Natalizumab Pan-European Study Group (2003) Natalizumab for active Crohn?s disease. N Engl J Med 348:24?32","journal-title":"N Engl J Med"},{"key":"CR26","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1517\/14728214.8.1.47","volume":"8","author":"Kovarik","year":"2003","unstructured":"Kovarik JM, Burtin P (2003) Immunosuppressants in advanced clinical development for organ transplantation and selected autoimmune diseases. Expert Opin Emerg Drugs 8:47?62","journal-title":"Expert Opin Emerg Drugs"},{"key":"CR27","doi-asserted-by":"crossref","first-page":"222","DOI":"10.4161\/cbt.2.3.360","volume":"2","author":"Huang","year":"2003","unstructured":"Huang S, Bjornsti MA, Houghton PJ (2003) Rapamycins: mechanism of action and cellular resistance. Cancer Biol Ther 2:222?232","journal-title":"Cancer Biol Ther"},{"key":"CR28","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1124\/jpet.102.045658","volume":"305","author":"Fujino","year":"2003","unstructured":"Fujino M, Funeshima N, Kitazawa Y, Kimura H, Amemiya H, Suzuki S, Li XK (2003) Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J Pharmacol Exp Ther 305:70?77","journal-title":"J Pharmacol Exp Ther"},{"key":"CR29","doi-asserted-by":"crossref","first-page":"12855","DOI":"10.1073\/pnas.96.22.12855","volume":"96","author":"Bourrie","year":"1999","unstructured":"Bourrie B, Bribes E, Esclangon M, Garcia L, Marchand J, Thomas C, Maffrand JP, Casellas P (1999) The neuroprotective agent SR 57746A abrogates experimental autoimmune encephalomyelitis and impairs associated blood-brain barrier disruption: implications for multiple sclerosis treatment. Proc Natl Acad Sci USA 96:12855?12859","journal-title":"Proc Natl Acad Sci"},{"key":"CR30","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1212\/WNL.59.7.990","volume":"59","author":"Neuhaus","year":"2002","unstructured":"Neuhaus O, Strasser-Fuchs S, Fazekas F, Kieseier BC, Niederwieser G, Hartung HP, Archelos JJ (2002) Statins as immunomodulators: comparison with interferon-beta 1b in MS. Neurology 59:990?997","journal-title":"Neurology"},{"key":"CR31","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(04)16205-3","volume":"363","author":"Vollmer","year":"2004","unstructured":"Vollmer T, Key L, Durkalski V, Tyor W, Corboy J, Markovic-Plese S, Preiningerova J, Rizzo M, Singh I (2004) Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 363:1607?1608","journal-title":"Lancet"},{"key":"CR32","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0165-5728(03)00264-9","volume":"142","author":"Eltayeb","year":"2003","unstructured":"Eltayeb S, Sunnemark D, Berg AL, Nordvall G, Malmberg A, Lassmann H, Wallstrom E, Olsson T, Ericsson-Dahlstrand A (2003) Effector stage CC chemokine receptor-1 selective antagonism reduces multiple sclerosis-like rat disease. J Neuroimmunol 142:75?85","journal-title":"J Neuroimmunol"},{"key":"CR33","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0165-5728(00)00265-4","volume":"108","author":"Dinter","year":"2000","unstructured":"Dinter H, Tse J, Halks-Miller M, Asarnow D, Onuffer J, Faulds D, Mitrovic B, Kirsch G, Laurent H, Esperling P, Seidelmann D, Ottow E, Schneider H, Tuohy VK, Wachtel H, Perez HD (2000) The type IV phosphodiesterase specific inhibitor mesopram inhibits experimental autoimmune encephalomyelitis in rodents. J Neuroimmunol 108:136?146","journal-title":"J Neuroimmunol"},{"key":"CR34","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/71466","volume":"6","author":"Steinman","year":"2000","unstructured":"Steinman L (2000) Multiple approaches to multiple sclerosis. Nat Med 6:15?16","journal-title":"Nat Med"},{"key":"CR35","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/71555","volume":"6","author":"Pitt","year":"2000","unstructured":"Pitt D, Werner P, Raine CS (2000) Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med 6:67?70","journal-title":"Nat Med"},{"key":"CR36","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/71548","volume":"6","author":"Smith","year":"2000","unstructured":"Smith T, Groom A, Zhu B, Turski L (2000) Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat Med 6:62?66","journal-title":"Nat Med"},{"key":"CR37","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.neuroscience.2004.01.019","volume":"125","author":"Wang","year":"2004","unstructured":"Wang SJ, Wang KY, Wang WC (2004) Mechanisms underlying the riluzole inhibition of glutamate release from rat cerebral cortex nerve terminals (synaptosomes). Neuroscience 125:191?201","journal-title":"Neuroscience"},{"key":"CR38","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0006-8993(03)03343-2","volume":"989","author":"Gilgun-Sherki","year":"2003","unstructured":"Gilgun-Sherki Y, Panet H, Melamed E, Offen D (2003) Riluzole suppresses experimental autoimmune encephalomyelitis: implications for the treatment of multiple sclerosis. Brain Res 989:196?204","journal-title":"Brain Res"},{"key":"CR39","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1191\/1352458502ms849xx","volume":"8","author":"Kalkers","year":"2002","unstructured":"Kalkers NF, Barkhof F, Bergers E, van Schijndel R, Polman CH (2002) The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study. Mult Scler 8:532?533","journal-title":"Mult Scler"},{"key":"CR40","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1517\/14656566.3.10.1411","volume":"3","author":"Finnerup","year":"2002","unstructured":"Finnerup NB, Gottrup H, Jensen TS (2002) Anticonvulsants in central pain. Expert Opin Pharmacother 3:1411?1420","journal-title":"Expert Opin Pharmacother"},{"key":"CR41","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1097\/00001756-200111160-00052","volume":"12","author":"Touil","year":"2001","unstructured":"Touil T, Deloire-Grassin MS, Vital C, Petry KG, Brochet B (2001) In vivo damage of CNS myelin and axons induced by peroxynitrite. Neuroreport 12:3637?3644","journal-title":"Neuroreport"},{"key":"CR42","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1093\/brain\/120.12.2149","volume":"120","author":"Redford","year":"1997","unstructured":"Redford EJ, Kapoor R, Smith KJ (1997) Nitric oxide donors reversibly block axonal conduction: demyelinated axons are especially susceptible. Brain 120:2149?2157","journal-title":"Brain"},{"key":"CR43","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/ana.10443","volume":"53","author":"Kapoor","year":"2003","unstructured":"Kapoor R, Davies M, Blaker PA, Hall SM, Smith KJ (2003) Blockers of sodium and calcium entry protect axons from nitric oxide-mediated degeneration. Ann Neurol 53:174?180","journal-title":"Ann Neurol"},{"key":"CR44","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.1152\/jn.00434.2003","volume":"90","author":"Lo","year":"2003","unstructured":"Lo AC, Saab CY, Black JA, Waxman SG (2003) Phenytoin protects spinal cord axons and preserves axonal conduction and neurological function in a model of neuroinflammation in vivo. J Neurophysiol 90:3566?3571","journal-title":"J Neurophysiol"},{"key":"CR45","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s001090050101","volume":"75","author":"Benveniste","year":"1997","unstructured":"Benveniste EN (1997) Role of macrophages\/microglia in multiple sclerosis and experimental allergic encephalomyelitis. J Mol Med 75:165?173","journal-title":"J Mol Med"},{"key":"CR46","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/135245850000600108","volume":"6","author":"Bartnik","year":"2000","unstructured":"Bartnik BL, Juurlink BH, Devon RM (2000) Macrophages: their myelinotrophic or neurotoxic actions depend upon tissue oxidative stress. Mult Scler 6:37?42","journal-title":"Mult Scler"},{"key":"CR47","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1750-3639.1999.tb00212.x","volume":"9","author":"Smith","year":"1999","unstructured":"Smith KJ, Kapoor R, Felts PA (1999) Demyelination: the role of reactive oxygen and nitrogen species. Brain Pathol 9:69?92","journal-title":"Brain Pathol"},{"key":"CR48","doi-asserted-by":"crossref","first-page":"S137","DOI":"10.1002\/ana.410320724","volume":"32","author":"Hall","year":"1992","unstructured":"Hall ED (1992) Novel inhibitors of iron-dependent lipid peroxidation for neurodegenerative disorders. Ann Neurol 32(Suppl):S137?S142","journal-title":"Ann Neurol"},{"key":"CR49","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0165-5728(02)00269-2","volume":"131","author":"Marracci","year":"2002","unstructured":"Marracci GH, Jones RE, McKeon GP, Bourdette DN (2002) Alpha lipoic acid inhibits T cell migration into the spinal cord and suppresses and treats experimental autoimmune encephalomyelitis. J Neuroimmunol 131:104?114","journal-title":"J Neuroimmunol"},{"key":"CR50","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00415-004-0348-9","volume":"251","author":"Gilgun-Sherki","year":"2004","unstructured":"Gilgun-Sherki Y, Melamed E, Offen D (2004) The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J Neurol 251:261?268","journal-title":"J Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-004-1509-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-004-1509-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-004-1509-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T15:03:53Z","timestamp":1559055833000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-004-1509-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":50,"journal-issue":{"issue":"S5","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["1509"],"URL":"https:\/\/doi.org\/10.1007\/s00415-004-1509-6","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,9]]}}}